Indivior (INDV) Trading 1.8% Higher

Indivior PLC (LON:INDV) traded up 1.8% on Thursday . The stock traded as high as GBX 112.50 ($1.47) and last traded at GBX 110.45 ($1.44). 303,432 shares were traded during mid-day trading, a decline of 88% from the average session volume of 2,440,000 shares. The stock had previously closed at GBX 108.55 ($1.42).

Several equities research analysts have recently weighed in on the company. Numis Securities reaffirmed a “buy” rating on shares of Indivior in a research report on Tuesday, February 5th. Royal Bank of Canada downgraded Indivior to a “sector performer” rating in a research report on Wednesday, December 12th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Indivior presently has a consensus rating of “Hold” and a consensus price target of GBX 260.60 ($3.41).

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Modern Readers and is the sole property of of Modern Readers. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at

Indivior Company Profile (LON:INDV)

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.

Featured Story: Can systematic risk be avoided?

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with's FREE daily email newsletter.

Leave a Reply